News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

FlowCardia, Inc. Launches FlowMate(TM) Injector to Optimize Performance of CROSSER(R) CTO Recanalization Catheter


10/6/2009 11:30:01 AM

SUNNYVALE, Calif., Oct. 6 /PRNewswire/ -- FlowCardia, Inc., a worldwide leader in the development of endovascular devices for the treatment of chronic total occlusions (CTOs), has launched the FlowMate Injector, which dramatically simplifies central lumen crossing of CTOs using the CROSSER CTO Recanalization Catheter.

FlowMate provides unparalleled convenience by granting full control of the procedure to a physician via a single foot pedal, which initiates FlowMate's precise saline delivery as well as the Generator which activates the CROSSER Catheter. Fixed injector settings are integrated into the FlowMate adding even greater convenience and ease of use. A single IV pole houses both the FlowMate and Generator allowing for complete system integration.

"This is a significant improvement to the CROSSER CTO Recanalization System and it takes most of the learning curve out of the equation," said Dr. Cezar Staniloae of St. Vincent's Hospital in New York. "Set up is fast and using the new system affords me more time to focus on the patient and specifically, crossing the chronic occlusion with the CROSSER Catheter."

"We are excited to add this important product to our portfolio and to see the benefits to physicians and patients through enhanced CROSSER Catheter performance," said Chris Barys, Chief Operating Officer of FlowCardia. "FlowMate allows for complete CROSSER Catheter system integration and puts the power into the physician's hands, even when faced with the most difficult CTOs."

The CROSSER Catheter is a minimally-invasive endovascular device that utilizes high-frequency, mechanical vibration to facilitate passage through blockages in the peripheral and coronary arteries. It is designed as a frontline therapy to enable central lumen crossing of chronically occluded arteries thereby maximizing physicians' therapeutic options. Over 7,500 CROSSER Catheter procedures have been performed to date by physicians around the world.

About FlowCardia, Inc.

FlowCardia, Inc. is a privately held medical device company established in 2002 to design and manufacture a portfolio of endovascular CTO recanalization products. The CROSSER CTO Recanalization Catheter, steerable support catheters, and Porter guidewires comprise a family of tools which enable physicians to quickly cross chronic total occlusions allowing for subsequent balloon angioplasty, atherectomy, and/or stent placement. Additional information is available on the company's web site at: www.flowcardia.com.

SOURCE FlowCardia, Inc.

CONTACT: Mark Page, Sr. Director, Marketing of FlowCardia, Inc.,
+1-408-617-0352, ext. 301

Web site: http://www.flowcardia.com/


Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES